J A Curiel, S Langa, A Ruiz de la Bastida, Á Peirotén, I Álvarez, J M Landete
{"title":"产马酚和不产马酚肠道微生物群的表型差异。","authors":"J A Curiel, S Langa, A Ruiz de la Bastida, Á Peirotén, I Álvarez, J M Landete","doi":"10.1163/18762891-bja00094","DOIUrl":null,"url":null,"abstract":"<p><p>Equol is an isoflavone produced by intestinal microbiota from daidzein. It has been assumed that individuals with equol-producing microbiota are those who mainly benefit from isoflavone consumption. However, no obvious genotypic differences can be found between the microbiota of equol-producing individuals and non-equol-producing individuals. The aim of this work was to find phenotypic differences in isoflavone metabolism between equol-producing and non-equol-producing intestinal microbiota. Of the 17 faecal samples used in this work, six produced equol from both daidzein and dihydrodaidzein (DHD); however, only equol-producing faecal samples produced 5-hydroxy-equol from genistein and dihydrogenistein (DHG). The equol producing microbiota metabolised most of daidzein, genistein, DHD and DHG present in the medium, while the metabolism of daidzein and genistein by non-equol producing microbiota is much lower, and they do not metabolise DHD and DHG. Moreover, equol-producing faecal samples produced lower concentrations of O-DMA than the non-equol-producing faecal samples. In addition, we demonstrated that most of the O-DMA is produced from daidzein. Therefore, there are important phenotypic differences between equol-producing and non-equol-producing intestinal microbiota, and these differences explain the differentiation between equol-producing and non-equol-producing individuals, and help to understand the metabolism of isoflavones by microbiota and how intestinal microbiota is responsible for the benefits of isoflavone intake.</p>","PeriodicalId":8834,"journal":{"name":"Beneficial microbes","volume":" ","pages":"1-11"},"PeriodicalIF":3.1000,"publicationDate":"2025-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Phenotypic differences between equol-producing and non-equol-producing intestinal microbiota.\",\"authors\":\"J A Curiel, S Langa, A Ruiz de la Bastida, Á Peirotén, I Álvarez, J M Landete\",\"doi\":\"10.1163/18762891-bja00094\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Equol is an isoflavone produced by intestinal microbiota from daidzein. It has been assumed that individuals with equol-producing microbiota are those who mainly benefit from isoflavone consumption. However, no obvious genotypic differences can be found between the microbiota of equol-producing individuals and non-equol-producing individuals. The aim of this work was to find phenotypic differences in isoflavone metabolism between equol-producing and non-equol-producing intestinal microbiota. Of the 17 faecal samples used in this work, six produced equol from both daidzein and dihydrodaidzein (DHD); however, only equol-producing faecal samples produced 5-hydroxy-equol from genistein and dihydrogenistein (DHG). The equol producing microbiota metabolised most of daidzein, genistein, DHD and DHG present in the medium, while the metabolism of daidzein and genistein by non-equol producing microbiota is much lower, and they do not metabolise DHD and DHG. Moreover, equol-producing faecal samples produced lower concentrations of O-DMA than the non-equol-producing faecal samples. In addition, we demonstrated that most of the O-DMA is produced from daidzein. Therefore, there are important phenotypic differences between equol-producing and non-equol-producing intestinal microbiota, and these differences explain the differentiation between equol-producing and non-equol-producing individuals, and help to understand the metabolism of isoflavones by microbiota and how intestinal microbiota is responsible for the benefits of isoflavone intake.</p>\",\"PeriodicalId\":8834,\"journal\":{\"name\":\"Beneficial microbes\",\"volume\":\" \",\"pages\":\"1-11\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2025-08-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Beneficial microbes\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1163/18762891-bja00094\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Beneficial microbes","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1163/18762891-bja00094","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MICROBIOLOGY","Score":null,"Total":0}
Phenotypic differences between equol-producing and non-equol-producing intestinal microbiota.
Equol is an isoflavone produced by intestinal microbiota from daidzein. It has been assumed that individuals with equol-producing microbiota are those who mainly benefit from isoflavone consumption. However, no obvious genotypic differences can be found between the microbiota of equol-producing individuals and non-equol-producing individuals. The aim of this work was to find phenotypic differences in isoflavone metabolism between equol-producing and non-equol-producing intestinal microbiota. Of the 17 faecal samples used in this work, six produced equol from both daidzein and dihydrodaidzein (DHD); however, only equol-producing faecal samples produced 5-hydroxy-equol from genistein and dihydrogenistein (DHG). The equol producing microbiota metabolised most of daidzein, genistein, DHD and DHG present in the medium, while the metabolism of daidzein and genistein by non-equol producing microbiota is much lower, and they do not metabolise DHD and DHG. Moreover, equol-producing faecal samples produced lower concentrations of O-DMA than the non-equol-producing faecal samples. In addition, we demonstrated that most of the O-DMA is produced from daidzein. Therefore, there are important phenotypic differences between equol-producing and non-equol-producing intestinal microbiota, and these differences explain the differentiation between equol-producing and non-equol-producing individuals, and help to understand the metabolism of isoflavones by microbiota and how intestinal microbiota is responsible for the benefits of isoflavone intake.
期刊介绍:
Beneficial Microbes is a peer-reviewed scientific journal with a specific area of focus: the promotion of the science of microbes beneficial to the health and wellbeing of man and animal. The journal contains original research papers and critical reviews in all areas dealing with beneficial microbes in both the small and large intestine, together with opinions, a calendar of forthcoming beneficial microbes-related events and book reviews. The journal takes a multidisciplinary approach and focuses on a broad spectrum of issues, including safety aspects of pro- & prebiotics, regulatory aspects, mechanisms of action, health benefits for the host, optimal production processes, screening methods, (meta)genomics, proteomics and metabolomics, host and bacterial physiology, application, and role in health and disease in man and animal. Beneficial Microbes is intended to serve the needs of researchers and professionals from the scientific community and industry, as well as those of policy makers and regulators.
The journal will have five major sections:
* Food, nutrition and health
* Animal nutrition
* Processing and application
* Regulatory & safety aspects
* Medical & health applications
In these sections, topics dealt with by Beneficial Microbes include:
* Worldwide safety and regulatory issues
* Human and animal nutrition and health effects
* Latest discoveries in mechanistic studies and screening methods to unravel mode of action
* Host physiology related to allergy, inflammation, obesity, etc.
* Trends in application of (meta)genomics, proteomics and metabolomics
* New developments in how processing optimizes pro- & prebiotics for application
* Bacterial physiology related to health benefits